Pharmacopsychiatry
September 1, 2011
Milan Scheidegger, Anke Henning, Martin Walter et al.
Background: Ketamine is a potent NMDA receptor antagonist with rapid antidepressant properties at subanaesthetic doses. This multimodal imaging study reveals the effects of a subanaesthetic ketamine infusion on fMRI-BOLD responses during an emotional processing task and their relationship to glutamatergic metabolite concentrations in the pregenual anterior cingulate cortex (PACC) assessed by...
Pharmacopsychiatry
September 1, 2011
Simone Grimm, Milan Scheidegger, Anke Henning et al.
Ketamine is a potent glutamatergic NMDA receptor antagonist with rapid antidepressant properties, thus providing a valuable research tool for the investigation of the neurobiology of major depressive disorder (MDD). Increasing evidence underscores the role of glutamate dependent neuroplasticity and glutamatergic neurotransmission and metabolism in the pathophysiology of MDD. This multimodal...
Journal of Neuroscience
August 10, 2011
Samuel A Neymotin, Maciej T Lazarewicz, Mohamed Sherif et al.
Abnormalities in oscillations have been suggested to play a role in schizophrenia. We studied theta-modulated gamma oscillations in a computer model of hippocampal CA3 in vivo with and without simulated application of ketamine, an NMDA receptor antagonist and psychotomimetic. Networks of 1200 multicompartment neurons [pyramidal, basket, and oriens-lacunosum moleculare (OLM) cells] generated...
Journal of Anesthesia
August 2011
Joon-Ho Lee, Sung-Hwan Cho, Sang-Hyun Kim et al.
We investigated the heat pain threshold (HPT) and temporal summation threshold (TST) before and after target-controlled infusion (TCI) of ketamine with an effect-site concentration (Ce) of 30 and 60 ng/ml. Healthy young volunteers (n = 20) were enrolled. A thermode was applied to the volar side of each volunteer's right forearm, and HPT and TST were measured before and after TCI of ketamine....
Psychological Medicine
August 1, 2011
Letter to the editor: does ketamine exert a fast-acting antidepressant effect via inhibition of pro-inflammatory cytokines?
Clinical Pharmacology & Therapeutics
August 2011
Marko A. Peltoniemi, Teijo I. Saari, Nora M. Hagelberg et al.
This study examined drug-drug interactions of oral S-ketamine with the cytochrome P450 (CYP) 2B6 inhibitor ticlopidine and the CYP3A inhibitor itraconazole. In this randomized, blinded, crossover study, 11 healthy volunteers ingested 0.2 mg/kg S-ketamine after pretreatments with oral ticlopidine (250 mg twice daily), itraconazole (200 mg once daily), or placebo in 6-day treatment periods at...
Anesthesia & Analgesia
July 26, 2011
Barbara Sinner, Oliver Friedrich, Wolfgang Zink et al.
61 citations
BACKGROUND: In the immature brain, neuronal Ca2+ oscillations are present during a time period of high plasticity and regulate neuronal differentiation and synaptogenesis. In this study we examined the long-term blockade of hippocampal Ca2+ oscillations, the role of the N-methyl-D-aspartate (NMDA) receptors and the effects of S(+)-ketamine on neuronal synapsin expression. METHODS: Hippocampal...
Addiction
July 21, 2011
Celia J. A. Morgan, Helen Valerie Curran
645 citations
AIMS: Ketamine remains an important medicine in both specialist anaesthesia and aspects of pain management. At the same time, its use as a recreational drug has spread in many parts of the world during the past few years. There are now increasing concerns about the harmful physical and psychological consequences of repeated misuse of this drug. The aim of this review was to survey and integrate...
Biological Psychology
July 13, 2011
Verner J Knott, Anne M Millar, Judy F McIntosh et al.
Given the cognitive-promoting properties of the nicotinic acetylcholinergic receptor (nAChR) agonist, nicotine, the increased prevalence of smoke-inhaled nicotine in schizophrenia has been interpreted as an attempt to self-correct cognitive deficits, which have been particularly pronounced in the attentional domain. As glutamatergic abnormalities have been implicated in these attentional...
American Journal of Psychiatry
July 1, 2011
Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation.